Send me a link:

*Text messaging rates may apply.

 Dow Down 0.93% Nasdaq Down 1.37%

ArQule Inc. (ARQL)

-NasdaqGM
1.33 Down 0.04(2.92%) 10:50AM EDT - Nasdaq Real Time Price
Prev Close:1.37
Open:1.37
Bid:1.34 x 400
Ask:1.35 x 500
1y Target Est:3.25
Beta:1.27
Next Earnings Date: 5-Aug-14ARQL Earnings announcement
Day's Range:1.33 - 1.37
52wk Range:1.29 - 2.94
Volume:30,928
Avg Vol (3m):319,148
Market Cap:83.42M
P/E (ttm):N/A
EPS (ttm):-0.42
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Comparison

Symbol% ChgMkt Cap
ARQLDown 2.92%83.42M
ARRYDown 4.95%507.73M
ASTX 0.00%N/A

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):6.65
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-14) :-0.49
Quarterly EPS Est (Jun-14) :-0.12
Mean Recommendation*:2.6
PEG Ratio (5 yr expected):-0.55

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback